Find Funding Opportunities

Returning 167 results

Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed)

RFA
Monday, October 29, 2018
Saturday, January 5, 2019
U54
RFA-NS-19-013

Funding Opportunity Purpose

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

Limited Competition: Restoring Research Resources Lost or Damaged Due to Hurricanes Harvey, Irma, and Maria (R24 Clinical Trial Optional)

RFA
Monday, October 29, 2018
Saturday, December 15, 2018
R24
RFA-OD-18-102

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to provide support to help restore research resources, including animal colonies and related materials and equipment that were lost or damaged due to Hurricanes Harvey, Irma, and Maria. Benefits of this award are restricted to the FEMA declared major disaster states, which are: Texas, Florida, US Virgin Islands, Puerto Rico, Georgia and South Carolina. Applications submitted in response to this announcement will be considered for funding only with funds received under the Bipartisan Budget Act of 2018 P.L. 115-123; P.L. 11572; and P.L. 11556. Funds will be provided in a single award with a 24-month budget and project period. No-cost extensions will not be available. Support will be considered for replacement only of those animals and other materials that were extant before Hurricanes Harvey, Irma, and Maria and were being used in connection with funded grant support or otherwise being used actively but were lost due to the hurricane(s). These funds cannot duplicate nor overlap with reimbursement provided by the Federal Emergency Management Agency (FEMA), under a contract for insurance, or by self-insurance.

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)

PAR
Friday, October 26, 2018
Wednesday, September 15, 2021
U01
PAR-19-039

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-18-NNN). The scope of this FOA encompasses Technical Readiness Level (TRL) 1-3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)

PAR
Friday, October 26, 2018
Wednesday, September 15, 2021
U01
PAR-19-040

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. The mission of the CounterACT Program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scaleable manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Early Screening for Autism Spectrum Disorder (R01 Clinical Trial Not Allowed)

RFA
Thursday, October 25, 2018
Tuesday, February 5, 2019
R01
RFA-MH-19-120

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R01 grant mechanism, while RFA-MH-19-121 uses the R21 grant mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for the R21 mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use this FOA (R01 mechanism).

Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed)

RFA
Thursday, October 25, 2018
Tuesday, February 5, 2019
R21
RFA-MH-19-121

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that would develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R21 grant mechanism, while RFA- MH-19-120 uses the R01 grant mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use the R01 mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for this FOA (R21 mechanism).

Emerging Global Leader Award (K43 Independent Clinical Trial Required)

PAR
Thursday, October 25, 2018
Thursday, November 5, 2020
K43
PAR-19-038

Funding Opportunity Purpose

This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

NINDS Morris K. Udall Center without Walls for Parkinsons Disease Research (P20 Clinical Trial Optional)

RFA
Thursday, October 25, 2018
Saturday, January 5, 2019
P20
RFA-NS-18-027

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area.

NINDS Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50 Clinical Trial Optional)

RFA
Thursday, October 25, 2018
Saturday, January 5, 2019
P50
RFA-NS-18-026

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge. Requirements include 1) a minimum of three research projects; 2) research cores that are each essential to accomplish the aims of at least two proposed research projects, plus an Administrative Core; 3) a mission statement and plan for career enhancement of Center trainees and investigators; and 4) a plan for effective outreach, including dissemination of Udall Center research results, to the local patient and advocacy community. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. A considerable degree of synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. The Udall Center Director (PD/PI) must be an established leader in scientific research with visionary leadership skills and proven expertise

BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)

RFA
Monday, October 22, 2018
Monday, June 28, 2021
U24
RFA-NS-19-006

Funding Opportunity Purpose

This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.

Pages